Fig. 1From: Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancerKaplan–Meier analysis for progression-free survival in patients between tumor downstaging and non-downstagingBack to article page